One of Glax­o­SmithK­line's top can­cer drug prospects goes down in 3rd straight set­back, leav­ing a $4B deal on life sup­port

One of Hal Bar­ron’s big-tick­et part­ner­ships has tak­en an­oth­er bad hit, fail­ing the third straight study in a se­ries of can­cer stud­ies and look­ing com­plete­ly worth­less.

Mer­ck KGaA has thrown in the tow­el on its Phase II study of bin­tra­fusp al­fa with gem­c­itabine plus cis­platin in the first-line treat­ment of pa­tients with lo­cal­ly ad­vanced or metasta­t­ic bil­iary tract can­cer af­ter con­clud­ing the en­deav­or was fu­tile.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER